Charles Wagner - Vertex Pharmaceuticals CFO, Executive Vice President

VRTX -- USA Stock  

USD 174.94  2.61  1.47%

  President
Mr. Charles F. Wagner was appointed as Chief Financial Officer, Executive Vice President of the company. Effective April 10, 2019
Age: 47  President Since 2019  MBA    
617-341-6100  http://www.vrtx.com
Wagner joins Vertex from Ortho Clinical Diagnostics, Inc. ? a Carlyle Group portfolio company, where he served as CFO and EVP, Finance. In this role, he had leadership responsibilities for all aspects of finance, accounting, tax, treasury, global information systems, lender relations, and acquisitions and divestitures, as well as shared responsibility for several enterprisewide projects. Prior to this, Mr. Wagner served as CFO for publicly traded Bruker Corporationrationrationration, Progress Software Corporationrationrationration and Millipore Corporationrationrationration. In addition to his corporate finance roles, Mr. Wagner served as an advisor at Bain & Company and Coopers & Lybrand. He received his BS in accounting from Boston ` and his MBA from Harvard Business School.

Management Efficiency

The company has return on total asset (ROA) of 9.99 % which means that it generated profit of $9.99 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 56.25 % meaning that it created $56.25 on every $100 dollars invested by stockholders.
The company currently holds 656.95M in liabilities with Debt to Equity (D/E) ratio of 12.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.67 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Paul WeningerPerrigo Company plc
2015
Alejandro BernalZoetis
2015
Roman TrawickiZoetis
2015
Marion McCourtRegeneron Pharmaceuticals
2018
Joseph LaRosaRegeneron Pharmaceuticals
2019
J RamachandranDr Reddys Laboratories Ltd
2016
Christopher FenimoreRegeneron Pharmaceuticals
2017
John WesolowskiPerrigo Company plc
2016
Raghav ChariDr Reddys Laboratories Ltd
2013
James MichaudPerrigo Company plc
2016
Jay MarkowitzRegeneron Pharmaceuticals
2017
Daniel PlewRegeneron Pharmaceuticals
2016
Clinton LewisZoetis
2018
George YancopoulosRegeneron Pharmaceuticals
2016
Thomas FarringtonPerrigo Company plc
2015
Jeffrey NeedhamPerrigo Company plc
2009
Scott JamisonPerrigo Company plc
2011
Douglas McCorkleRegeneron Pharmaceuticals
2007
Ronald JanishPerrigo Company plc
2015
James DillardPerrigo Company plc
2019
Stefan WeiskopfZoetis
2013

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Current Sentiment - VRTX

Vertex Pharmaceuticals Investor Sentiment

Most of Macroaxis users are at this time bullish on Vertex Pharmaceuticals Incorpor. What is your outlook on investing in Vertex Pharmaceuticals Incorpor? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased over 20 shares of
few hours ago
Traded for 15.09
Purchased few shares of
few hours ago
Traded for 42.34
Purchased few shares of
few hours ago
Traded for 119.16
Also please take a look at World Market Map. Please also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Search macroaxis.com